Diabetes (Metabolic Disorder)

PB (MDT)- 3010 (Biosimilar) Diabrid Technology / NobleCleav® Technology

Paras Biopharmaceuticals Finland Oy has developed 4 products (API) for type I and type II Diabetes Mellitus (DM).

PCT Patent Filing

The process for the production of insulin "Glargine" and the Diabrid Technology developed for the production of Insulin "Aspart" are currently being prepared for worldwide PCT patent submission. These technological innovations by Paras Biopharmaceuticals Finland Oy reduce the costs of industrial production of Glargine and Insulin "Aspart" achieving higher economic advantages.

Indications
Type I
Type II



Diabetes Mellitus
Product status » SDS-PAGE High expression.
» Mass spectrometry : Confirmation of N-and C- terminal, and AA sequence.
Technology status Soon to be available for licensing within scale-up production.

Recombinant stable E. Coli Clone exhibits deposits of the Metabolic Disorder Treatment (PB (MDT) – 3010) product inside the cells (EM@39000-Paras Rights Reserved).

SDS-PAGE-Gel image (left) showing marker (lane1), homogenization broth (lane2) and separation of Metabolic Disorder Treatment product (lane3).

Meet Us At

Connect with us

Paras Biopharmaceuticals
Finland Oy
,

Kiviharjunlenkki 10, OULU,
FI-90220 Finland

P: +358 442709462

Dr Ashesh Kumar
E: kumar.ashesh@parasbiopharma.com
P: +358 (0) 400207380

Dr Mark Jackson
E: mark.jackson@parasbiopharma.com
P:+358 (0) 442905993

Skype: Paras.Finland